Pharmaids Pharmaceuticals Limited

Date: 11.11.2026

To
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Outcome of the Board Meeting held on November 11, 2026

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), and in continuation to our intimation dated November 05, 2026 regarding the Notice for the Board Meeting, we hereby inform that the Board of Directors of Pharmaids Pharmaceuticals Limited ("Company") in their Meeting held today i.e., Wednesday, November 11, 2026, have, inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the quarter and half year ended September 30, 2026.

Pursuant to Regulation 33 of Listing Regulations, a copy of the Financial Results along with Limited Review Report issued by the Statutory Auditors of the Company, M/s PPKG & Co, Chartered Accountants, is enclosed herewith.

The Financial Results are also available on the website of the Company at https://www.pharmaids.com

The Board Meeting commenced at 03:30 P.M. and concluded at 04:30 P.M.

Kindly take the same on your record and oblige.

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat

Digitally signed by Prasanna Subramanya Bhat
Date: 2026.11.11 19:18:36 +05'30'

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)

PPKG & Co
Chartered Accountants

Batgach
& AFFILIATES
A NETWORK APPROVED BY ICAI

Independent Auditor's Review Report on standalone unaudited quarterly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of Standalone Unaudited financial results of Pharmaids Pharmaceuticals Limited for the quarter and half year ended 30th September 2026 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 009655S)

Giridhari Lal Toshniwal
(Partner)
(Membership No. 205140)
UDIN: 26205140BKVPPG5150

Place: Hyderabad
Date: 11th November 2026

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended 30th September, 2026

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended Sep 30, 2026 (Unaudited)	Quarter ended Jun 30, 2026 (Unaudited)	Quarter ended Sep 30, 2025 (Unaudited)	Half Year ended Sep 30, 2026 (Unaudited)	Half Year ended Sep 30, 2025 (Unaudited)	Year ended Mar 31, 2026 (Audited)
Income						
Revenue from operations	106.02	-	596.55	106.02	708.08	1,060.25
Other income	4.64	4.59	19.07	9.23	53.79	66.04
Total income	**110.66**	**4.59**	**615.61**	**115.25**	**761.86**	**1,126.29**
Expenses						
Cost of materials consumed	105.49	-	928.75	105.49	986.22	1,091.05
Purchase of stock-in-trade	-	-	-	-	39.60	39.60
Changes in inventories of finished goods and work-in-progress	-	-	(276.78)	-	(267.48)	11.50
Employee benefits expense	70.69	69.26	159.86	139.95	299.61	539.54
Finance costs	61.50	57.30	101.95	118.80	213.02	330.15
Depreciation and amortisation expense	5.33	5.68	5.65	11.01	10.75	21.38
Other expenses	20.44	17.64	242.61	38.08	595.74	799.45
Total expenses	**263.46**	**149.89**	**1,162.05**	**413.34**	**1,877.46**	**2,832.67**
Profit/ (Loss) before exceptional items and tax	**(152.80)**	**(145.30)**	**(546.43)**	**(298.09)**	**(1,115.60)**	**(1,706.38)**
Exceptional items	-	420.00	313.05	420.00	313.08	311.04
Profit/ (Loss) before tax	**(152.80)**	**274.70**	**(233.38)**	**121.91**	**(802.51)**	**(1,395.34)**
Tax expense						
Current tax	-	-	-	-	-	-
Deferred tax	(40.61)	61.21	(68.15)	20.60	(200.98)	(351.62)
Total Tax Expense	(40.61)	61.21	(68.15)	20.60	(200.98)	(351.62)
Profit/ (Loss) for the year	**(112.19)**	**213.49**	**(165.23)**	**101.30**	**(601.53)**	**(1,043.72)**



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended 30th September, 2026

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended Sep 30, 2026 (Unaudited)	Quarter ended Jun 30, 2026 (Unaudited)	Quarter ended Sep 30, 2025 (Unaudited)	Half Year ended Sep 30, 2026 (Unaudited)	Half Year ended Sep 30, 2025 (Unaudited)	Year ended Mar 31, 2026 (Audited)
Other comprehensive income						
(i) Items that will not be reclassified subsequently to profit or loss						
Re-measurement on defined benefit plans and equity instruments	0.97	0.97	0.24	1.95	0.48	3.90
Income tax effect	(0.25)	(0.25)	(0.06)	(0.51)	(0.12)	(1.01)
(ii) Items that will be reclassified subsequently to profit or loss						
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-	-	-
Income tax effect	-	-	-	-	-	-
Other comprehensive income for the year, net of taxes	0.72	0.72	0.18	1.44	0.35	2.88
Total comprehensive income for the year	**(111.47)**	**214.21**	**(165.06)**	**102.74**	**(601.18)**	**(1,040.84)**
Paid-up Equity share capital (Face value Rs. 10/- per share)	**3,526.78**	**3,526.78**	**3,526.78**	**3,526.78**	**3,526.78**	**3,526.78**
Other Equity (excluding revaluation reserve)						1,811.26
Earnings per equity share						
Basic (in Rs)	(0.32)	0.61	(0.47)	0.29	(1.70)	(2.96)
Diluted (in Rs)	(0.32)	0.61	(0.47)	0.29	(1.70)	(2.96)

Place: Bengaluru
Date : 11-11-2026

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699

Pharmaids Pharmaceuticals Limited ★ Bengaluru 560013

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979
Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation
Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended 30th September, 2026

Notes to Accounts:

1. The above unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its respective meetings held on Nov 11, 2026.


2. The unaudited standalone financials results of the company have been prepared in accordance with the Ind AS as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules 2015 (as amended) and in accordance with the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3. The company operates in a single segment of providing Contract Research and Manufacturing Services.

4. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.

Place: Bengaluru
Date : 11-11-2026

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited



Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Standalone Balance Sheet

All figures in Rs. Lacs unless otherwise specified

Particulars	As at 30 Sep 2026 (Unaudited)	As at 31 March 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	786.24	790.55
Capital work-in-progress	659.07	546.97
Right-of-use assets	7.82	14.52
Financial assets		
(i) Investments	5,254.48	5,254.48
(ii) Other financial assets	342.20	342.16
Deferred tax assets (net)	844.47	865.58
Other non-current assets	-	-
Total non-current assets	**7,894.28**	**7,814.27**
Current assets		
Inventories	-	-
Financial assets		
(i) Trade receivables	36.37	138.02
(ii) Cash and cash equivalents	0.25	10.79
(iii) Other financial assets	292.38	284.38
Other current assets	237.96	148.54
Total current assets	**566.97**	**581.73**
TOTAL ASSETS	**8,461.25**	**8,396.00**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	3,526.78	3,526.78
Other equity	1,914.00	1,811.26
Total equity	**5,440.79**	**5,338.04**
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	1,757.00	1,491.15
(ii) Lease liabilities	-	1.34
Provisions	6.18	1.31
Other non-current liabilities		
Total non-current liabilities	**1,763.18**	**1,493.80**
Current liabilities		
Financial liabilities		
(i) Borrowings	673.80	554.08
(ii) Lease liabilities	10.45	16.21
(iii) Trade payables		
total outstanding dues of micro and small enterprises	-	-
total outstanding dues of creditors other than micro and small enterprises	-	102.90
(iv) Other financial liabilities	545.24	720.22
Provisions	-	4.55
Other current liabilities	27.78	166.21
Total Current Liabilities	**1,257.28**	**1,564.16**
TOTAL EQUITY AND LIABILITIES	**8,461.25**	**8,396.00**

Place: Bengaluru
Date : 11-11-2026

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699

Pharmaids Pharmaceuticals Limited Bengaluru 560013

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya PlantationBangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Standalone Statement of Cash Flows

All figures in Rs. Lacs unless otherwise specified

Particulars	Period ended 30 Sep 2026 (Unaudited)	Period ended 30 Sep 2025 (Unaudited)
Cash flows from operating activities		
Net Profit Before Tax	121.91	(802.51)
Adjustments to reconcile profit before tax to net cash flows:		
Depreciation	11.01	10.75
Interest income	(9.23)	(53.79)
Finance Cost	118.80	213.02
Liabilities written back		
Provision for gratuity	2.27	3.05
Provision for bad debts	-	
Gain on sale of assets		(316.25)
Share of loss in partnership firm	-	61.35
Loss on exit from subsidiary	-	2.45
Other Non cash adjustments	-	(47.01)
Adjustments for changes in working capital:		
(Increase)/decrease in inventories	-	605.33
(Increase)/decrease in trade receivables	101.65	(657.42)
(Increase)/decrease in other financial assets	0.32	104.68
(Increase)/decrease in other current assets	(89.42)	73.07
Increase/(decrease) in trade payables	(102.90)	29.34
Increase/(decrease) in other financial liabilities	(113.84)	116.47
Increase/(decrease) in other provisions	-	(5.78)
Increase/(decrease) in other current liabilities	(138.42)	260.40
Cash generated from/(used in) operations	**(97.85)**	**(402.85)**
Income tax paid	-	
Net cash flows generated from/(used in) operating activities (A)	**(97.85)**	**(402.85)**
Cash flows from investing activities		
Purchase of property, plant and equipment incl. CWIP	(112.10)	(14.02)
Sale of property, plant and equipment	-	1,955.94
Capex acquired on Credit	111.15	
Interest on bank deposits	0.88	46.35
Investment in Fixed Deposit	-	(11.53)
Investment in subsidiaries/ associates	-	-
Consideration received on Exit from subsidiary	-	206.65
Loans given	-	(54.75)
Net cash flow generated from/(used in) investing activities (B)	**(0.07)**	**2,128.64**
Cash flow from Financing activities		
Repayment of borrowing	(647.15)	(2,185.85)
Proceeds from borrowing	1,032.73	460.00
Interest on loan	(289.23)	(29.54)
Repayment of lease liabilities	(8.97)	(8.61)
Net cash flow generated from/(used in) financing activities (C)	**87.38**	**(1,764.01)**
Net increase in cash and cash equivalents (A+B+C)	(10.54)	(38.21)
Cash and cash equivalents at the beginning of the year	10.79	46.93
Cash and cash equivalents at the end of the year	**0.25**	**8.71**
Cash and cash equivalents comprise		
Cash on hand	0.10	0.61
Balances with banks in current & deposit accounts	0.15	8.10
Deposits with original maturity of less than 3 months	-	
Total cash and cash equivalents	**0.25**	**8.71**

Place: Bengaluru
Date : 11-11-2026

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699

Pharmaids Pharmaceuticals Limited ★ Bengaluru 560013

Independent Auditor's Review Report on consolidated unaudited quarterly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Pharmaids Pharmaceuticals Limited (Holding Company)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Pharmaids Pharmaceuticals Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiaries for the quarter and half year ended 30th September 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
   i. Adita Bio Sys Private Limited
   ii. Spring Labs (step down subsidiary)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of 1 subsidiary and 1 step down subsidiary included in the consolidated unaudited financial results, whose financial results reflect total assets of Rs 3665.22 lakhs as at 30th September 2026 and total revenues of Rs. 739.68 Lakhs, total net(loss) after tax of Rs. (95.06) Lakhs and total comprehensive (loss) of Rs. (93.96) lakhs for the half year ended 30th September 2026, respectively and cash flows (net) of Rs. 12.89 lakhs for the period ended 30th September 2026 as considered in the consolidated unaudited financial results.

   These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.



Our conclusion on the Consolidated Financial Statement is not modified in respect of the above matters.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 009655S)

Girdhari Lal Toshniwal
(Partner)
(Membership No. 205140)
UDIN: 26205140PRWNOJ3195

Place: Hyderabad
Date: 11th November 2026

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2026

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended Sep 30, 2026 (Unaudited)	Quarter ended Jun 30, 2026 (Unaudited)	Quarter ended Sep 30, 2025 (Unaudited)	Half Year ended Sep 30, 2026 (Unaudited)	Half Year ended Sep 30, 2025 (Unaudited)	Year ended Mar 31, 2026 (Audited)
Income						
Revenue from operations	433.56	412.14	860.50	845.69	1,526.86	2,788.24
Other income	5.56	4.83	22.15	10.39	26.16	28.88
Total income	**439.12**	**416.97**	**882.65**	**856.08**	**1,553.02**	**2,817.12**
Expenses						
Cost of materials consumed	173.27	98.66	983.97	271.93	1,227.36	1,474.07
Purchase of stock-in-trade	49.98	53.00	45.18	102.99	153.24	243.12
Changes in inventories of finished goods and work-in-progress	(0.22)	10.05	(274.10)	9.82	(274.99)	(1.93)
Employee benefits expense	249.86	246.61	318.09	496.47	736.85	1,337.74
Finance costs	65.57	60.37	107.66	125.94	227.20	349.15
Depreciation and amortisation expense	48.97	48.57	46.75	97.54	107.37	202.69
Other expenses	89.03	78.26	389.71	167.29	753.85	1,089.03
Total expenses	**676.46**	**595.52**	**1,617.25**	**1,271.98**	**2,930.89**	**4,693.86**
Profit/ (Loss) before exceptional items and tax	**(237.34)**	**(178.55)**	**(734.60)**	**(415.89)**	**(1,377.87)**	**(1,876.74)**
Exceptional items	-	420.00	298.78	420.00	298.82	246.46
Profit/ (Loss) before tax	**(237.34)**	**241.45**	**(435.82)**	**4.11**	**(1,079.05)**	**(1,630.28)**
Tax expense						
Current tax	-	-	-	-	-	-
Tax paid for earlier years	-	-	-	-	-	-
Deferred tax	(56.43)	54.30	(112.88)	(2.13)	(298.44)	(473.09)
Total Tax Expense	(56.43)	54.30	(112.88)	(2.13)	(298.44)	(473.09)
Profit/ (Loss) for the year	**(180.91)**	**187.15**	**(322.94)**	**6.24**	**(780.61)**	**(1,157.19)**
Other comprehensive income						
(i) Items that will not be reclassified subsequently to profit or loss						
Re-measurement on defined benefit plans and equity instruments	1.73	1.73	2.58	3.47	3.69	6.94
Income tax effect	(0.46)	(0.46)	(0.67)	(0.93)	(0.88)	(1.85)
(ii) Items that will be reclassified subsequently to profit or loss						
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-	-	-
Income tax effect	-	-	-	-	-	-
Other comprehensive income for the year, net of taxes	1.27	1.27	1.91	2.54	2.81	5.08
Total comprehensive income for the year	**(179.64)**	**188.42**	**(321.03)**	**8.78**	**(777.81)**	**(1,152.11)**

Pharmaids Pharmaceuticals Limited ★ Bengaluru 560073

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2026

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended Sep 30, 2026 (Unaudited)	Quarter ended Jun 30, 2026 (Unaudited)	Quarter ended Sep 30, 2025 (Unaudited)	Half Year ended Sep 30, 2026 (Unaudited)	Half Year ended Sep 30, 2025 (Unaudited)	Year ended Mar 31, 2026 (Audited)
Profit/ (Loss) attributable to:						
Equity holders of the Holding company	(210.01)	220.53	(318.15)	10.53	(739.44)	(1,171.69)
Non-controlling interest	29.10	(33.38)	(4.79)	(4.29)	(41.18)	14.51
Profit/ (Loss) for the year	**(180.91)**	**187.15**	**(322.94)**	**6.24**	**(780.61)**	**(1,157.19)**
Other comprehensive income attributable to:						
Equity holders of the Holding company	1.25	1.25	1.91	2.50	2.80	5.01
Non-controlling interest	0.02	0.02	0.00	0.04	0.00	0.07
Other comprehensive income for the year	**1.27**	**1.27**	**1.91**	**2.54**	**2.81**	**5.08**
Total comprehensive income attributable to:						
Equity holders of the Holding company	(208.75)	221.78	(316.24)	13.03	(736.63)	(1,166.68)
Non-controlling interest	29.11	(33.36)	(4.79)	(4.25)	(41.17)	14.58
Total comprehensive income for the year	**(179.64)**	**188.42**	**(321.03)**	**8.78**	**(777.81)**	**(1,152.11)**
Paid-up Equity share capital (Face value Rs. 10/- per share)	**3,526.78**	**3,526.78**	**3,526.78**	**3,526.78**	**3,526.78**	**3,526.78**
Other Equity (excluding revaluation reserve)						**1,238.57**
Earnings per equity share						
Basic (in Rs)	(0.60)	0.63	(0.90)	0.03	(2.09)	(3.32)
Diluted (in Rs)	(0.60)	0.63	(0.90)	0.03	(2.09)	(3.32)

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Whole Time Director
DIN: 00021699

Pharmaids Pharmaceuticals Limited ★ Bengaluru 560013

Place: Bengaluru
Date: 11-11-2026

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2026

Notes to Accounts:

1. The Unaudited Consolidated Financial Results of Pharmaids Pharmaceuticals Limited (The Holding Company) and its subsidiaries (together referred to as Group) have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter and in accoradance with the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations. 2015, as amended.

2. The Unaudited Consolidated Financial Results for the quarter and half year ended 30th Sep 2026 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Holding Company at their respective Meetings held on Nov 11, 2026.

3. The group operates in a single segment of providing Contract Research and Manufacturing Services.

4. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.

Place: Bengaluru
Date: 11-11-2026

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Pharmaids Pharmaceuticals Limited ★ Bengaluru 560013

Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya PlantationBangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Consolidated Balance Sheet

All figures in Rs. Lacs unless otherwise specified

Particulars	As at 30 Sep 2026 (Unaudited)	As at 31 March 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,987.85	2,000.17
Capital work-in-progress	796.38	734.76
Right-of-use assets	197.79	212.19
Other Intangible Assets	-	-
Goodwill on Business purchase and consolidation	3,141.66	3,141.66
Financial assets		
(i) Other financial assets	403.09	399.25
Deferred tax assets (net)	1,229.00	1,173.03
Other non-current assets	-	-
Total non-current assets	**7,755.77**	**7,661.05**
Current assets		
Inventories	18.18	18.28
Financial assets		
(i) Trade receivables	334.24	377.73
(ii) Cash and cash equivalents	15.70	14.19
(iii) Other financial assets	263.30	263.12
Other current assets	399.99	512.33
Total current assets	**1,031.42**	**1,185.66**
TOTAL ASSETS	**8,787.19**	**8,846.71**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	3,526.78	3,526.78
Other equity	1,251.60	1,460.35
Equity attributable to the owners of the Company	**4,778.38**	**4,987.13**
Non-controlling Interest	(9.35)	(38.46)
Total equity	**4,769.03**	**4,948.67**
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	1,495.38	1,206.12
(ii) Lease liabilities	181.10	181.24
(iii) Other financial liabilities	180.00	180.00
Provisions	27.37	24.99
Total non-current liabilities	**1,883.85**	**1,592.35**
Current liabilities		
Financial liabilities		
(i) Borrowings	1,054.92	1,017.92
(ii) Lease liabilities	42.28	54.08
(iii) Trade payables		
total outstanding dues of micro and small enterprises	55.31	49.77
total outstanding dues of creditors other than micro and small enterprises	156.21	245.61
(iv) Other financial liabilities	765.23	889.24
Provisions	-	-
Other current liabilities	60.34	49.12
Total Current Liabilities	**2,134.30**	**2,305.74**
TOTAL EQUITY AND LIABILITIES	**8,787.19**	**8,846.77**

Place: Bengaluru
Date: 11-11-2026

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Whole Time Director
DIN: 00021699

Pharmaids Pharmaceuticals Limited ★ Bengaluru 560013

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya PlantationBangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Consolidated Statement of Cash Flows

All figures in Rs. Lacs unless otherwise specified

Particulars	Period ended 30 Sep 2026 (Unaudited)	Period ended 30 Sep 2025 (Unaudited)
Cash flows from operating activities		
Net Profit Before Tax	4.11	(1,079.05)
Adjustments to reconcile profit before tax to net cash flows:		
Depreciation	97.54	107.37
Interest income	(12.44)	(21.65)
Finance Cost	129.83	227.20
Provision for gratuity	8.24	6.32
(Gain)/ Loss on sale of fixed asset	-	(316.25)
Loss/(Gain) on exit from subsidiary	-	16.71
Other Non cash adjustments	-	(47.01)
Adjustments for changes in working capital:		
(Increase)/decrease in inventories	22.87	601.90
(Increase)/decrease in trade receivables	13.27	(693.85)
(Increase)/decrease in other financial assets	0.32	104.68
(Increase)/decrease in other current assets	39.06	90.66
Increase/(decrease) in trade payables	(71.13)	72.53
Increase/(decrease) in other financial liabilities	(36.58)	240.61
Increase/(decrease) in other provisions	-	(5.78)
Increase/(decrease) in other current liabilities	(193.21)	322.98
Cash generated from/(used in) operations	**1.89**	**(372.63)**
Income tax paid	-	-
Net cash flows generated from/(used in) operating activities (A)	**1.89**	**(372.63)**
Cash flows from investing activities		
Purchase of property, plant and equipment incl. CWIP	(127.31)	(73.19)
Sale of property, plant and equipment	-	1,955.94
Capex acquired on Credit	111.15	-
Interest on bank deposits	6.25	52.80
Investment in Fixed Deposit	(90.42)	(11.53)
Consideration received on Exit from subsidiary	-	206.65
Subsidy received	-	37.11
Repayment of loans advanced	5.00	-
Loans given	-	(18.75)
Net cash flow generated from/(used in) investing activities (B)	**(95.33)**	**2,149.04**
Cash flow from Financing activities		
Repayment of borrowing	(647.15)	(2,185.85)
Proceeds from borrowing	1,104.63	458.58
Repayment of partners'capital in subsidiary	-	-
Interest on loan	(320.52)	(67.21)
Repayment of lease liabilities	(41.17)	(40.32)
Net cash flow generated from/(used in) financing activities (C)	**95.80**	**(1,834.80)**
Net increase in cash and cash equivalents (A+B+C)	2.35	(58.39)
Cash and cash equivalents at the beginning of the year	13.35	82.29
Cash and cash equivalents at the end of the year	**15.70**	**23.90**
Cash and cash equivalents comprise		
Cash on hand	1.01	1.69
Balances with banks in current & deposit accounts	14.69	22.21
Total cash and cash equivalents	**15.70**	**23.90**

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Place: Bengaluru
Date: 11-11-2026

Venu Madhava Kaparthy
Whole Time Director
DIN: 00021699

Pharmaids Pharmaceuticals Limited ★ Bengaluru 560013